International Edition
Latest News
Health

Korea Launches Initiative to Localize Essential Medical Devices

South Korea's push to manufacture essential medical devices domestically advanced on September 4, 2026, as regulators and development officials convened a joint forum in Seoul to align regulatory science with early-stage engineering. The Medical Device STEP-UP Initiative Framework…

South Korea's push to manufacture essential medical devices domestically advanced on September 4, 2026, as regulators and development officials convened a joint forum in Seoul to align regulatory science with early-stage engineering.

The Medical Device STEP-UP Initiative Framework

The forum, titled the 2026 Medical Device STEP-UP Initiative Integrated Forum, took place at the YTN Newsquare in Seoul. Project Group Director Kim Beop-min stated during the opening session that the program—formerly known as the pan-ministry medical device commercialization support governance—links regulatory science and technical assistance directly to a project’s Technology Readiness Level. Following the conclusion of the initial six-year funding cycle that ran from 2020 through 2025, the newly launched second phase focuses heavily on bridging the gap between laboratory prototypes and clinical application.

According to Kim, developing high-difficulty medical technologies requires integrating evaluation standards and regulatory pathways from the earliest design phases rather than addressing them only after product completion. The STEP-UP platform coordinates efforts across the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare to streamline approvals.

Regulatory Support and Domestic Manufacturing Goals

Kang noted that active participation by regulatory authorities in multi-agency research groups helps prevent approval bottlenecks, pointing to numerous product authorizations secured during the first phase of the government-backed initiative.

The 2026 program prioritizes life-saving hardware that is not currently manufactured within South Korea. During the technical sessions, research teams detailed development strategies for several critical devices:

  • Implantable cardiac pacemakers and high-precision leads
  • Fully magnetically levitated cardiopulmonary blood pumps
  • Non-central circulation artificial blood vessels for hemodialysis
  • Vascular tubes and catheters designated for cardiopulmonary surgeries
  • Peripheral vascular thrombectomy catheters designed to clear blood clots

Kim Tae-hyung, a headquarters director within the project group, presented the overarching operational strategy for these essential devices, outlining milestones for domestic clinical trials and commercial scaling.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”